Cargando…
A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China
BACKGROUND: While China is a major manufacturer of artemisinin and its derivatives, it lags as a global leader in terms of the total export value of anti-malarial drugs as finished pharmaceutical products ready for marketing and use by patients. This may be due to the limited number of World Health...
Autores principales: | Huang, Yangmu, Pan, Ke, Peng, Danlu, Stergachis, Andy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883522/ https://www.ncbi.nlm.nih.gov/pubmed/29615066 http://dx.doi.org/10.1186/s12936-018-2303-8 |
Ejemplares similares
-
A survey of nongovernmental organizations on their use of WHO’s prequalification programme
por: Giralt, Ariadna Nebot, et al.
Publicado: (2020) -
The production and exportation of artemisinin-derived drugs in China: current status and existing challenges
por: Huang, Yangmu, et al.
Publicado: (2016) -
Implementing interprofessional bedside rounding at the prequalification stage
por: Tuite, Daniel R, et al.
Publicado: (2016) -
The quality of anti-malarial medicines in Embu County, Kenya
por: Ndwigah, Stanley, et al.
Publicado: (2018) -
The Manufacturers’ Perspective on World Health Organization Prequalification of In Vitro Diagnostics
por: Morin, Sébastien, et al.
Publicado: (2018)